Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.51 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.38 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1811347 | 1.00 | LPAR1 (0.51) | LPAR1GPR132FFAR4RIPK1ALKBH1 | |
| SCHEMBL1811344 | 1.00 | LPAR1 (0.51) | LPAR1GPR132FFAR4RIPK1ALKBH1 | |
| SCHEMBL1811242 | 0.89 | LPAR1 (0.64) | LPAR1GPR132FFAR4PTK2 | |
| SCHEMBL1811240 | 0.89 | LPAR1 (0.64) | LPAR1GPR132FFAR4PTK2 | |
| SCHEMBL1811246 | 0.89 | LPAR1 (0.64) | LPAR1GPR132FFAR4PTK2 | |
| SCHEMBL1809294 | 0.88 | LPAR1 (0.65) | LPAR1GPR132 | |
| SCHEMBL1809290 | 0.88 | LPAR1 (0.65) | LPAR1GPR132 | |
| SCHEMBL1809292 | 0.88 | LPAR1 (0.65) | LPAR1GPR132 | |
| SCHEMBL1808339 | 0.81 | LPAR1 (0.58) | LPAR1GPR132 | |
| SCHEMBL1808336 | 0.81 | LPAR1 (0.58) | LPAR1GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496556-B1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2018-12-26 | — | — | EP | disclosed |
| US-9018383-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-04-28 | — | — | US | disclosed |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-03-27 | — | — | US | disclosed |
| US-8618304-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-10-18 | — | — | US | disclosed |
| EP-2496556-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011053948-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | LPAR1 4/4885GPR132 518/4885FFAR4 108/4885 |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | LPAR1 4/4885GPR132 518/4885FFAR4 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.